ข้อถือสิทธิสิ่งที่ขอถือสิทธิ:1. An

ข้อถือสิทธิ

สิ่งที่ขอถือสิทธิ:


1. An isolated antibody or antibody :ชิ้นส่วนย่อยของมัน ซึ่งประกอบรวมด้วย an antigen binding region that ยึดเกาะ to a V-domain lg ซับเพรสเซอร์ of T cell Activation (VISTA), โดยที่ binding of the antibody or ชิ้นส่วนย่อย แอนติบอดี to VISTA modulates or enhances an immune response.

2. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ the ชิ้นส่วนย่อย แอนติบอดี is a Fab, F(ab')2, or scFv antibody :ชิ้นส่วนย่อย.

3. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1 which ประกอบรวมด้วย an antibody constant region.

4. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ VISTA is expressed on a hematopoietic cell.

5. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ the hematopoietic cell is a myeloid lineage cell and/or a lymphocyte.

6. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ the hematopoietic cell is a monocyte or a neutrophil.

7. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ the hematopoietic cell is a T cell.

8. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ the hematopoietic cell is a B cell, a natural killer (NK) cell or a natural killer T (NKT) cell.

9. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1, โดยที่ VISTA is expressed on a tumor cell.

10. The antibody or ชิ้นส่วนย่อย แอนติบอดี of ข้อถือสิทธิ 1 โดยที่ VISTA is expressed in a tumor microenvironment (TME).


- 77 -



11. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-10, ซึ่งประกอบรวมต่อไปด้วย one or more สายหนัก complementary determining regions (CDRs) and one or more สายเบา CDRs; โดยที่ the one or more สายหนัก CDRs ประกอบรวมด้วย an amino acid sequence selected from SEQ ID NOs:l-3, 7-9, 13-15, 19-21, 25-27, 31-33 and the one or more สายเบา CDRs ประกอบรวมด้วย an amino acid sequence selected from SEQ ID NOs:4-6,
10-12, 16-18, 22-24, 28-30, 34-36).


12. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-10, ซึ่งประกอบรวมต่อไปด้วย at least one สายหนัก and at least one สายเบา.

13. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one heavy chain ประกอบรวมด้วย SEQ ID NO:l-3.

14. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one สายเบา ประกอบรวมด้วย SEQ ID N0:4-6.

15. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one heavy chain ประกอบรวมด้วย SEQ ID NO:l-3 and โดยที่ at least one สายเบา ประกอบรวมด้วย SEQ ID N0:4-6.

16. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one heavy chain ประกอบรวมด้วย the heavy chain variable region sequence as shown in SEQ ID N0:37-40.

17. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one สายเบา ประกอบรวมด้วย the สายเบา variable region sequence as shown in SEQ ID N0:41-45.

18. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to ข้อถือสิทธิ 12, โดยที่ at least one heavy chain ประกอบรวมด้วย the heavy chain variable region sequence as shown in SEQ ID N0:37-40, and โดยที่ at least one สายเบา ประกอบรวมด้วย the สายเบา variable region sequence as shown in SEQ ID NO: 41-45.


- 78 -


19. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody is a โมโนโคลนอล antibody.

20. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody is a ฮิวเมไนซ์ antibody.

21. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody ประกอบรวมด้วย a human constant region.

22. An antibody or ชิ้นส่วนย่อย แอนติบอดี according to any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody molecule is specific for an เอพิโทป within the amino acid sequence SEQ ID NO: 46.

23. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody ยึดเกาะ to an เอพิโทป of VISTA with an แอฟฟินิตี้ of at least lxl0-9 liter/mole.

24. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody ยึดเกาะ to an เอพิโทป of VISTA with an แอฟฟินิตี้ of at least lxl o' liter/mole.

25. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the antibody ยึดเกาะ to an เอพิโทป of VISTA with an แอฟฟินิตี้ of at least 1xl0-7 liter/mole.

26. The antibody or ชิ้นส่วนย่อย แอนติบอดี of any one of ข้อถือสิทธิ 1-18, โดยที่ the modulation of the immune response ประกอบรวมด้วย an increase in CD45+ ลิวโคไซต์, CD4+ T cells, or CD8+ T cells, or a combination ของมัน, or a decrease in VISTA-expressing immune cells.

Results (English) 1:

Right message.What would the rights:1. An isolated antibody or antibody: sub parts of it, which, as with an antigen binding region that adhere to a lg V-domain liner express of sensor T cell Activation (VISTA), by the binding of the antibody or antibodies to Subpart modulates or enhances immune response an VISTA.2. The antibody or antibodies-text of Subpart 1, right by where the piece is a Fab antibody fragment, F (ab ') 2, or antibody scFv: subpart.3. The antibody or antibodies hold the text of Subpart 1 which, as with an antibody constant region.4. The antibody or antibodies-text of Subpart 1, right by where the VISTA is expressed on hematopoietic cell a.5. The antibody or antibodies-text of Subpart 1, right by where the myeloid lineage hematopoietic cell is a cell and/or a lymphocyte.6. The antibody or antibodies-text of Subpart 1, right by where the hematopoietic cell monocyte neutrophil is a or a.7. The antibody or antibodies-text of Subpart 1, right by where the hematopoietic cell is a T cell.8. The antibody or antibodies-text of Subpart 1, right by where the hematopoietic cell is a B cell, natural killer (NK), a cell or a natural killer T (NKT) cell.9. The antibody or antibodies-text of Subpart 1, right by where the VISTA is expressed on a tumor cell.10. The antibody or antibodies hold the text of Subpart 1 without a tumor microenvironment is expressed in VISTA (TME). -77-11. The antibody or antibodies of any sub one piece of text right 1-10, which has included one or more wires with complementary determining regions (CDRs), heavy and light cables, one or more CDRs at one or more; the heavy cables, CDRs with an amino acid sequence, as selected from SEQ ID NOs: l-3, 7-9, 13-15, 19-21, 25-27, 31-33, and the one or more wires, light with an amino acid as CDRs sequence SEQ ID NOs from selected: 4-6,10-12, 16-18, 22-24, 28-30, 34-36).12. The antibody or antibodies of any sub one piece of text right 1-10, which has included at least one line with heavy and light cables, one at least.1. An antibody or antibodies according to Subpart holds the right message, at least one 12-without the heavy chain integration with NO ID SEQ: l-3.2. An antibody or antibodies according to Subpart holds the right message, at least one 12-by the light line, as with the SEQ ID N0:4-6.3. An antibody or antibodies according to Subpart holds the right message, at least one 12-without the heavy chain integration with NO ID SEQ: l-3 and at least one light cable without integration with N0 ID SEQ: 4-6.4. An antibody or antibodies according to Subpart holds the right message, at least one 12-without the heavy chain as the heavy chain variable region with a sequence as shown in SEQ ID N0:37-40.5. An antibody or antibodies according to Subpart holds the right message, at least one 12-without wires, light the lighter line, as with variable region as shown in sequence SEQ ID N0:41-45.6. An antibody or antibodies according to Subpart holds the right message, at least one 12-without the heavy chain as the heavy chain variable region with a sequence as shown in SEQ ID N0:37-40, and at least one line, without light as the light cord with variable region in SEQ ID NO shown as sequence: 41-45. -78-19. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody is a monoclonal antibody all-in.20. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody is a hip wame nice antibody.21. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody constant region composed by a human.22. An antibody or antibodies according to Subpart any one message of liberty 1-18, by which the antibody molecule is specific for an ACE master amino acid within the app, fullscreen sequence SEQ ID NO: 46.23. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody to an adhesive ACE pigeon of VISTA app with master an affinity of at least lxl0-9 liter/mole.24. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody to an adhesive ACE pigeon of VISTA app with master an affinity of at least lxl o ' liter/mole.25. The antibody or antibodies of any sub one piece of text right 1-18, by which the antibody to an adhesive ACE pigeon of VISTA app with master an affinity of at least 1xl0-7 liter/mole.26. The antibody or antibodies of any sub one piece of text right 1-18, by which the modulation of the immune response, as with an increase in CD4 CD45 +, Leu +, co T cells, CD8 + T cells or, or a combination of them, or a decrease in immune cells VISTA-expressing.

Results (English) 2:

Claims that claim: 1. An isolated antibody or antibody: small parts of it. Which comprises an antigen binding region that adhesion to a V-domain lg suppressor of T cell Activation (VISTA), the binding of the antibody or antibody fragments, small modulates or enhances an immune response to VISTA. 2. the antibody or antibody fragment product of claim 1, where the pieces antibody fragment is a Fab, F (ab ') 2, or scFv antibody: small parts. 3. The antibody or antibody fragment product of claim 1 which comprises an antibody Constant Region. 4. The antibody or antibody fragment product of claim 1, which is expressed on a VISTA hematopoietic Cell. 5. The antibody. antibody fragment or piece of claim 1, where the myeloid lineage hematopoietic Cell is a Cell and / or a lymphocyte. 6. the antibody or antibody fragment product of claim 1, where the hematopoietic cell is a monocyte. or a neutrophil. 7. the antibody or antibody fragment product of claim 1, where the hematopoietic Cell is a T Cell. 8. the antibody or antibody fragment product of claim 1, where the hematopoietic cell is. a B Cell, a Natural Killer (NK) Cell or a Natural Killer T (NKT) Cell. 9. the antibody or antibody fragment product of claim 1, which is expressed on a tumor VISTA Cell. 10. the antibody. antibody fragment or piece of claim 1 which is expressed in a tumor microenvironment VISTA (TME). - 77 - 11. the antibody or antibody fragment pieces of any one of claims 1-10, which include the establishment. with one or more hard-line complementary determining regions (CDRs) and one or more wires, light CDRs; Where the one or more hard-line CDRs comprises an amino acid sequence selected from SEQ ID NOs: l-3, 7-9, 13-15, 19-21, 25-27, 31-33 and the one or more. line light CDRs comprises an amino acid selected from SEQ ID nós Sequence: 4-6, 10-12, 16-18, 22-24, 28-30, 34-36). 12. The antibody or antibody fragments, small. of any one of claims 1-10, which include the establishment of at least one hard-line and at least one light line. 13. an antibody or antibody fragment product according to claim 12, in which at least one. SEQ ID NO heavy chain comprises: L-3. 14. an antibody or antibody fragment product according to claim 12, in which at least one light line comprises SEQ ID N0: 4-6. 15. an. antibody or antibody fragment product according to claim 12, in which at least one heavy chain comprises SEQ ID NO: l-3 and the at least one light line comprises SEQ ID N0: 4-6. 16. . an antibody or antibody fragment product according to claim 12, in which at least one heavy chain comprises the Heavy chain as shown in SEQ ID Variable Region Sequence N0: 37-40. 17. an antibody or small pieces. Antibodies according to claim 12, in which at least one line of light comprises the light lines shown in SEQ ID Variable Region Sequence as N0: 41-45. 18. an antibody or antibody fragment product according to claim 12. , where at least one heavy chain comprises the heavy chain variable region sequence as shown in SEQ ID N0: 37-40, and by the at least one light cable assembly line with the light variable region sequence as shown in SEQ ID. NO: 41-45. - 78 - 19. the antibody or antibody fragment pieces of any one of claims 1-18, in which the antibody is a monoclonal antibody. 20. the antibody or antibody fragments, small. of any one of claims 1-18, in which the antibody is a nice Hughes Medical antibody. 21. the antibody or antibody fragment pieces of any one of claims 1-18, where the antibody assembly. with a Human Constant Region. 22. an antibody or antibody fragment product according to any one of claims 1-18, where the antibody molecule is specific for an episode of Masters within the amino acid sequence SEQ ID NO: 46. . 23. the antibody or antibody fragment pieces of any one of claims 1-18, where the antibody binding to an episode of Masters of VISTA with an AFL infinity of at least lxl0-9 liter /. Mole. 24. the antibody or antibody fragment pieces of any one of claims 1-18, where the antibody binding to an episode of Masters of VISTA with an AFL infinity of at least lxl o 'liter. / Mole. 25. the antibody or antibody fragment pieces of any one of claims 1-18, where the antibody binding to an episode of Masters of VISTA with an AFL infinity of at least 1xl0-7. liter / Mole. 26. the antibody or parts small antibody of any one of claims 1-18, where the modulation of the immune response comprises an increase in CD45 + W Coast site, CD4 + T cells, or CD8 + T. cells, or a combination thereof, or a decrease in VISTA-expressing immune cells.